Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-23-256998
Filing Date
2023-10-16
Accepted
2023-10-16 17:24:04
Documents
17
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A d559256d10ka.htm   iXBRL 10-K/A 48302
2 EX-23.1 d559256dex231.htm EX-23.1 3502
3 EX-31.1 d559256dex311.htm EX-31.1 3788
4 EX-31.2 d559256dex312.htm EX-31.2 3833
  Complete submission text file 0001193125-23-256998.txt   256900

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA ikt-20221231.xsd EX-101.SCH 4943
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ikt-20221231_cal.xml EX-101.CAL 656
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ikt-20221231_def.xml EX-101.DEF 1661
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20221231_lab.xml EX-101.LAB 22792
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20221231_pre.xml EX-101.PRE 17572
11 EXTRACTED XBRL INSTANCE DOCUMENT d559256d10ka_htm.xml XML 7335
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 263407249 | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39676 | Film No.: 231328028
SIC: 2836 Biological Products, (No Diagnostic Substances)